Latest Insider Transactions at Passage Bio, Inc. (PASG)
This section provides a real-time view of insider transactions for Passage Bio, Inc. (PASG). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Passage BIO, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Passage BIO, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 11
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
80
-0.0%
|
$0
$0.8 P/Share
|
|
Dec 10
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,015
-0.1%
|
$0
$0.8 P/Share
|
|
Dec 09
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
54,181
-0.7%
|
$0
$0.84 P/Share
|
|
Dec 06
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,903
-0.27%
|
$0
$0.82 P/Share
|
|
Dec 04
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
76,200
-0.98%
|
$0
$0.79 P/Share
|
|
Nov 27
2024
|
Lynx1 Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
29,300
+0.33%
|
$0
$0.67 P/Share
|
|
Nov 26
2024
|
Lynx1 Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
167,055
+1.85%
|
$0
$0.71 P/Share
|
|
Nov 25
2024
|
Lynx1 Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
259,998
+2.91%
|
$0
$0.56 P/Share
|
|
Sep 19
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
39,300
-0.5%
|
$0
$0.71 P/Share
|
|
Sep 18
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
25,631
-0.33%
|
$0
$0.73 P/Share
|
|
Sep 17
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
111,400
-1.4%
|
$0
$0.73 P/Share
|
|
Sep 16
2024
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
63,100
-0.79%
|
$0
$0.74 P/Share
|
|
Feb 13
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,638
-3.26%
|
$0
$0.97 P/Share
|
|
Feb 13
2024
|
Kathleen Borthwick CFO |
SELL
Open market or private sale
|
Direct |
1,470
-4.91%
|
$0
$0.97 P/Share
|
|
Feb 10
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.05%
|
-
|
|
Feb 10
2024
|
Kathleen Borthwick CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+11.79%
|
-
|
|
Jan 02
2024
|
Edgar B. Cale GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
15,813
-25.58%
|
$0
$0.91 P/Share
|
|
Jan 02
2024
|
Kathleen Borthwick CFO |
SELL
Open market or private sale
|
Direct |
10,672
-29.15%
|
$0
$0.91 P/Share
|
|
Jan 02
2024
|
Mark S Forman CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
15,813
-25.89%
|
$0
$0.91 P/Share
|
|
Dec 31
2023
|
Edgar B. Cale GC & CORPORATE SECRETARY |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+44.72%
|
-
|
|
Dec 31
2023
|
Kathleen Borthwick CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+45.04%
|
-
|
|
Dec 31
2023
|
Mark S Forman CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+45.01%
|
-
|
|
Jul 28
2023
|
Simona King Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,453
-32.31%
|
$0
$0.88 P/Share
|
|
Jul 28
2023
|
Simona King Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
31,250
+46.85%
|
-
|
|
Jun 28
2023
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
575,195
+6.68%
|
$0
$0.84 P/Share
|
|
Jun 27
2023
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
617,382
+7.64%
|
$0
$0.84 P/Share
|
|
Jun 16
2023
|
Alexandros Fotopoulos Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
4,052
-12.37%
|
$0
$0.93 P/Share
|
|
Jun 15
2023
|
Alexandros Fotopoulos Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+27.63%
|
-
|
|
Apr 18
2023
|
Simona King Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,053
-50.0%
|
$2,053
$1.05 P/Share
|
|
Apr 18
2023
|
Simona King Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
-
|
|
Dec 01
2022
|
Sandip Kapadia |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$5,000
$1.19 P/Share
|
|
Nov 22
2022
|
Alexandros Fotopoulos Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
3,720
-15.52%
|
$3,720
$1.33 P/Share
|
|
Nov 22
2022
|
Alexandros Fotopoulos Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+34.28%
|
-
|
|
Sep 19
2022
|
Monika Maria Toernsen Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,681
-33.62%
|
$1,681
$1.51 P/Share
|
|
Sep 15
2022
|
Monika Maria Toernsen Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
May 04
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
303,500
+4.25%
|
$303,500
$1.94 P/Share
|
|
May 03
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
221,500
+3.28%
|
$221,500
$1.93 P/Share
|
|
Mar 21
2022
|
Bruce A Goldsmith CEO and President |
BUY
Open market or private purchase
|
Direct |
10,000
+38.49%
|
$30,000
$3.15 P/Share
|
|
Jan 20
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
369,100
+5.27%
|
$1,845,500
$5.42 P/Share
|
|
Jan 19
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
43,300
+0.69%
|
$216,500
$5.11 P/Share
|
|
Jan 18
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
114,700
+1.81%
|
$573,500
$5.46 P/Share
|
|
Jan 14
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
10,300
+0.17%
|
$51,500
$5.6 P/Share
|
|
Jan 13
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
41,800
+0.68%
|
$209,000
$5.52 P/Share
|
|
Jan 12
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.62%
|
$500,000
$5.65 P/Share
|
|
Jan 11
2022
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,200
+0.14%
|
$41,000
$5.53 P/Share
|
|
Dec 08
2021
|
Jill M. Quigley Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
71,975
+16.33%
|
$0
$0.23 P/Share
|
|
May 21
2021
|
Bruce A Goldsmith CEO and President |
BUY
Open market or private purchase
|
Direct |
2,000
+25.05%
|
$26,000
$13.12 P/Share
|
|
May 21
2021
|
Richard Steven Morris Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,171
+28.47%
|
$28,223
$13.82 P/Share
|
|
Mar 15
2021
|
Gary Romano Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-91.92%
|
$210,000
$21.41 P/Share
|
|
Mar 15
2021
|
Gary Romano Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$80,000
$8.07 P/Share
|